Brought to you by 
Oncodesign applies its Nanocyclix technology to Sanofi's kinase projects
26 Mar 2013
Executive Summary
Oncodesign SA (drug discovery tools for oncology therapeutics) will apply its Nanocyclix medicinal chemistry technology to several of Sanofi’s kinase target programs in development. Specific projects and therapeutic areas were not disclosed.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Technologies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Oncodesign applies its Nanocyclix technology to Sanofi's kinase projects
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice